Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (362)	4/9/2002 11:21:14 AM
From: nigel bates	Respond to of 1022

Diversys contd. Management Robert T Connelly is Chief Executive Officer of Diversys. Mr Connelly was formerly CEO of Veritas Pharmaceuticals Inc., an early stage private US company with proprietary technology for the in vivo functional imaging of cancer and other diseases. Prior to Veritas, Mr Connelly spent over five years with IGEN International Inc. At IGEN he served as Senior Vice President of Sales and Marketing and General Manager of IGEN's Life Sciences Business Unit. Before IGEN Mr. Connelly spent more than eleven years in sales, marketing and management with the diagnostics division of Abbott Laboratories. Ian Tomlinson PhD is a Founder and Chief Scientific Officer of Diversys. Before joining Diversys full time, Dr Tomlinson was a Group Leader at the MRC Laboratory of Molecular Biology in Cambridge, UK. He is a recognised expert in the field of antibodies and antibody engineering and during his time at the MRC-LMB developed many of the new antibody library and array technologies used by Diversys. In addition, he is co-founder of the Human Proteome Organisation (HUPO). Pamela A Hay is Chief Commmercial Officer of Diversys. Prior to joining Diversys, Ms Hay was SVP, Corporate Development and Strategic Opportunities at Dyax Corp., a public biotechnology which utilizes phage display to discover novel therapeutic, diagnostic and separation products. Before Dyax, Ms Hay was General Counsel at T Cell Sciences (now Avant Immunotherapeutics) and Corporate Counsel at Biogen Inc. Montgomery Mars is Chief Financial Officer and General Manager of Diversys' Proteomics Business Unit. Mr Mars has led business development and M&A activities at a number of biotechnology companies, including Mercator Genetics, Ixsys (now Applied Molecular Evolution) and Advanced Tissue Sciences. Mr Mars also was the Senior Vice President of Corporate Development and Finance at Beyond.com and practiced law with the law firm of Latham & Watkins. Kevin Moulder PhD is Vice President of R & D of Diversys. He was formally Director, Medical Research with Biogen Inc, a fully integrated biotechnology company based in the US focused on the discovery and development of recombinant protein and immunoglobulin based drugs. Prior to Biogen, Dr. Moulder spent three years as Director, Experimental Therapeutics with Ares Advanced Technology in the US and three years as Group Leader with SmithKline Beecham pharmaceuticals in the UK....